share_log

The Journal Of Clinical And Aesthetic Dermatology Published Arcutis Biotherapeutics' Outcomes Of A Comprehensive Evaluation By An Expert Dermatologist Panel Assessing The Formulation Ingredients Of ZORYVE Topical Foam, 0.3%

Benzinga ·  May 13 20:08
  • Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on review of formulation data
  • Crodafos CES, used in ZORYVE foam, is suitable for a wide variety of skin and hair types
  • Findings from this formulation review underscore the suitability of ZORYVE foam for use on all affected areas of the body, and all hair types, in the management of seborrheic dermatitis

WESTLAKE VILLAGE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Journal of Clinical and Aesthetic Dermatology (JCAD) published the outcomes of a comprehensive evaluation by an expert dermatologist panel assessing the formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%. ZORYVE foam is a once-daily steroid-free treatment for seborrheic dermatitis. The published article supports the use of ZORYVE foam in all hair and skin types.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment